• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    TScan Therapeutics, Inc. - Common Stock (NQ:TCRX)

    0.3415 +0.0015 (+0.44%)
    Streaming Delayed Price Updated: 3:05 PM EDT, Sep 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 260,510
    Open 0.3400
    Bid (Size) 0.3411 (100)
    Ask (Size) 0.3421 (100)
    Prev. Close 0.3400
    Today's Range 0.3251 - 0.3478
    52wk Range 0.2902 - 2.570
    Shares Outstanding 23,976,942
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Unusual volume stocks in Tuesday's session ↗
    Via Chartmill
    What's going on in today's session ↗
    Via Chartmill

    Performance

    YTD
    -66.5%
    -66.5%
    1 Month
    -54.7%
    -54.7%
    3 Month
    -65.1%
    -65.1%
    6 Month
    -63.7%
    -63.7%
    1 Year
    -80.4%
    -80.4%

    More News

    Read More
    Here are the top movers in Wednesday's session. ↗
    Via Chartmill
    Which stocks are gapping on Wednesday? ↗
    Via Chartmill
    News headline image
    TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
    From Cellares
    Via Business Wire
    News headline image
    TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
    From TScan Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
    Via Benzinga
    News headline image
    Which stocks are moving on Monday? ↗
    Via Chartmill
    News headline image
    Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga
    News headline image
    Gapping stocks in Monday's session ↗
    Via Chartmill
    News headline image
    Discover the top movers in Monday's pre-market session. ↗
    Via Chartmill

    Frequently Asked Questions

    Is TScan Therapeutics, Inc. - Common Stock publicly traded?
    Yes, TScan Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does TScan Therapeutics, Inc. - Common Stock trade on?
    TScan Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for TScan Therapeutics, Inc. - Common Stock?
    The ticker symbol for TScan Therapeutics, Inc. - Common Stock is TCRX on the Nasdaq Stock Market
    What is the current price of TScan Therapeutics, Inc. - Common Stock?
    The current price of TScan Therapeutics, Inc. - Common Stock is 0.3415
    When was TScan Therapeutics, Inc. - Common Stock last traded?
    The last trade of TScan Therapeutics, Inc. - Common Stock was at 09/28/26 03:05 PM ET
    What is the market capitalization of TScan Therapeutics, Inc. - Common Stock?
    The market capitalization of TScan Therapeutics, Inc. - Common Stock is 8.19M
    How many shares of TScan Therapeutics, Inc. - Common Stock are outstanding?
    TScan Therapeutics, Inc. - Common Stock has 8M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.